Lipifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipifen

Property Description
Active ingredient Atorvastatin
Form Film-coated Tablets
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
General use Lipid-lowering agent
Origin Synthetic

What Type of Medicine is Lipifen and its Classification?

Lipifen is a prescription synthetic medication classified as a statin, belonging to the pharmacological group known as HMG-CoA Reductase Inhibitors. Its active compound is Atorvastatin, which is a single-ingredient product designed for oral administration, typically formulated as film-coated tablets. This classification means its primary therapeutic effect is achieved by directly modulating the body’s internal lipid production pathways. The identity of Lipifen is strictly tied to Atorvastatin, a high-potency entity that targets the source of endogenous cholesterol production. This medicine works by helping to slow the body's production of cholesterol.


Composition and General Purpose of Atorvastatin

The composition of Lipifen is defined by its core active substance, Atorvastatin Calcium, contained within the solid pharmaceutical excipients necessary for the tablet form. As a highly selective lipid-lowering agent, the general purpose of this medication is to help manage and adjust the balance of various fats, specifically lipoproteins, in the bloodstream. This overall function makes it essential in the domain of Hyperlipidemia and related Dyslipidemias. The medication is designed to achieve a substantial reduction of LDL-C ("bad cholesterol") and Total-C (total cholesterol), which is the fundamental objective for patients with elevated lipid levels. Statins are used for lowering elevated LDL-C levels, as this class of medicine is intended for significantly lowering "bad" cholesterol levels. A typical use scenario involves long-term management for adult patients diagnosed with primary hypercholesterolemia, where this medication provides the specific action needed to modify the lipid profile.

Regulatory References

  1. NIH/NHLBI Treatment Guidelines
  2. NICE Guideline Recommendations

What side effects are possible with Lipifen?

Possible Side Effects and Safety Information

The official safety profile for Lipifen (Atorvastatin) is based on classifications from government health authorities, detailing adverse reactions by their documented frequency and the physiological systems affected. Reactions are formally classified as Common, Uncommon, Rare, and Very Rare.


Adverse Reaction Scope and Classification

Adverse reactions are organized by System-Organ-Class, primarily involving Musculoskeletal and Gastrointestinal systems, as well as Hepatobiliary and Nervous System disorders. Reactions classified as Common (may affect up to 1 in 10 people) include nasopharyngitis, headache, and myalgia (muscle pain), along with general gastrointestinal disturbances like constipation and nausea.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights serious adverse reactions, which, while infrequent, include Rhabdomyolysis (severe muscle breakdown) and Hepatotoxicity (liver injury), including fatal and non-fatal hepatic failure. The medicine's use is contraindicated in individuals with active liver disease or unexplained, persistent elevations in serum transaminases, according to official labeling.


Specific Safety Patterns

The safety profile includes specific population-based statements, such as the caution advised for patients with pre-existing hepatic impairment or those who consume substantial quantities of alcohol. Furthermore, the regulatory text notes that serious muscle effects, such as myopathy, are not limited to the start of treatment and can occur at any time during exposure to the medication.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Lipifen (Atorvastatin)

Official regulatory information emphasizes that an overdose of Lipifen must be managed with professional medical intervention. Immediate medical attention must be sought in all cases of suspected overdose, as directed by government guidance on emergency response for pharmaceuticals. The dedicated overdose sections of regulatory labels, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics, do not explicitly document unique symptoms or signs that result from an acute overdosage of atorvastatin.

The regulatory profile mandates management based on procedural care, highlighting two key constraints on treatment options:


Official Overdose Statements

Management Aspect Regulatory Statement
Specific Treatment (Antidote) There is no specific treatment (antidote) documented for atorvastatin overdosage.
Required Response Management must be symptomatic and supportive measures instituted as required.
Clearance Constraint Haemodialysis is not expected to significantly enhance clearance due to extensive plasma protein binding.

This structure confirms that emergency personnel must focus on stabilization and supportive care, treating any observed clinical effects, as there is no specific agent available to reverse the drug's effects directly or through mechanical removal.

Therapeutic Uses of Lipifen

What Lipifen Treats: Main Uses and Benefits

Lipifen (Atorvastatin) plays a role in the long-term management of chronic lipid conditions, relevant for the management of associated cardiovascular risk. Its use is centered on treating underlying, often asymptomatic imbalances in blood fats rather than immediate symptom relief. The medication's core therapeutic purpose involves its action as a lipid-modifying agent.


Indications and Preventative Benefit

The primary application involves managing Dyslipidemia and Hypercholesterolemia. It is relevant in conditions such as Primary Hypercholesterolemia, Mixed Dyslipidemia, and the inherited Familial Hypercholesterolemia. By supporting the maintenance of stable lipid levels, Lipifen provides a preventative benefit by assisting with the reduction of the risk of severe symptomatic events like heart attack, stroke, and angina. This proactive approach offers patients the benefit of supporting long-term functional stability and is applied extensively in high-risk scenarios, including primary and secondary prevention.

“This medication is considered relevant where therapeutic goals, such as substantial LDL-C lowering, are appropriate in situations where intensive lipid management is needed due to complex risk profiles.”


Quick Fact: Management of Future Symptom Burden
Management of Asymptomatic Imbalance Lipifen is commonly used to help manage the underlying physiological stress of elevated blood fats, which is associated with the potential for acute symptomatic episodes that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lipifen

The official regulatory profile for Lipifen (Atorvastatin) strictly defines eligibility based on age, physiological state, and underlying health conditions.


Populations for Whom Use is Contraindicated

Lipifen must not be used in the following patient groups, as defined by absolute regulatory prohibitions:

  • Patients with Active Liver Disease, including unexplained persistent elevations of liver enzymes.
  • Individuals with known Hypersensitivity to the active ingredient (atorvastatin).
  • Women who are Pregnant or Breastfeeding (lactating). Women of childbearing potential are officially required to use effective contraception during therapy.

Age-Related Eligibility and Restrictions

Use is officially established for Adults and for Pediatric Patients aged 10 years and older for specific forms of high cholesterol. The use of Lipifen is not established in children younger than 10 years old.


Conditions Requiring Caution

While not absolutely prohibited, official labeling identifies populations that require caution and close monitoring due to increased risk factors for muscle effects (myopathy). These include patients with Renal Impairment, Uncontrolled Hypothyroidism, and Advanced Age (65 years and older).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lipifen (Atorvastatin) interacts with specific medicinal products, foods, and substances, primarily by altering the drug's plasma concentration or by increasing the risk of muscle-related adverse effects. Official regulatory documents classify these interactions based on their mechanism and severity.


Pharmacokinetic and Musculoskeletal Risk Interactions

The co-administration of strong CYP3A4 inhibitors (such as certain antifungals and antibiotics) significantly increases Atorvastatin plasma concentrations, necessitating dose restrictions as documented in the regulatory label. This mechanism of increased exposure is also observed with inhibitors of drug transport proteins like OATP1B1 and P-glycoprotein.

Combining Lipifen with Fibric Acid Derivatives (e.g., Gemfibrozil) or high-dose Niacin (ge 1 g/day) increases the officially documented pharmacodynamic risk of myopathy and rhabdomyolysis.

Regulatory Constraints and Substance Interactions

The co-administration of Glecaprevir/Pibrentasvir is strictly contraindicated due to a high risk of adverse outcomes and increased exposure. The antibiotic Rifampin requires simultaneous administration with Lipifen to prevent a documented reduction in the medicine's effectiveness. Consumption of large quantities of Grapefruit Juice (defined as ge 1.2 liters per day) is restricted because it causes a documented increase in Atorvastatin plasma levels, while excessive alcohol consumption is associated with an increased risk of hepatic adverse effects.

Mechanism of Action

Lipifen (Atorvastatin) acts through two primary and interconnected mechanistic domains that influence systemic lipid homeostasis.

Inhibition of Hepatic Cholesterol Synthesis

The drug's primary action involves competitive inhibition of the HMG-CoA Reductase (HMGR) enzyme within the liver cells. By blocking this rate-limiting step in the Mevalonate Pathway, Lipifen halts the internal synthesis of cholesterol and related isoprenoid intermediates, initiating the cascade of effects that influence systemic lipid modulation.

Enhanced Receptor-Mediated Lipoprotein Clearance

The reduction of cholesterol synthesis within the liver triggers a homeostatic feedback loop, which significantly up-regulates the expression of LDL Receptors on the hepatocyte surface. These newly expressed receptors actively enhance the catabolism and removal of circulating Low-Density Lipoprotein Cholesterol (LDL-C) and Very-Low-Density Lipoprotein (VLDL) from the bloodstream, thereby leading to the modulation of the circulating lipoprotein profile.

Vascular and Cellular Function Modulation

A secondary mechanistic domain involves the reduction of isoprenoid intermediates, which modulates the function of small signaling proteins (GTPases) in the arterial wall. This pleiotropic effect influences the function of the blood vessel lining (endothelium) and affects local inflammatory signaling within the vascular system.

Dosage and Administration Information

How to Use Lipifen

Lipifen (Atorvastatin) is utilized in clinical practice according to standardized usage patterns. The official route of administration for this medicine is oral, supplied as film-coated tablets in standard strengths of 10 mg, 20 mg, 40 mg, and 80 mg.


Administration and Dosage Regimen

The established dosing schedule requires the medication to be taken once daily (q.d.). The initial dose is typically 10 mg or 20 mg, though specific circumstances, such as the need for substantial LDL-C reduction, may lead to a starting dose of 40 mg. The maximum authorized daily dose is 80 mg. Doses are not adjusted on a daily basis but are typically reviewed and changed by a healthcare professional at intervals of four weeks or more based on the individual's lipid response.


Usage Context and Special Instructions

Lipifen offers flexibility regarding its timing, as it can be taken at any time of day and administered with or without food. This medication is intended for long-term, chronic management of lipid disorders, functioning as an adjunct to a comprehensive lipid-lowering diet. The tablets must be swallowed whole and should not be crushed, broken, or chewed.

Regarding missed timing, if a dose is skipped, the instruction is to skip the missed dose entirely and resume the normal daily schedule with the next dose; doubling up on doses is not advised. For specific populations, no dosage adjustment is required for patients with impaired renal function, and specific lower maximum doses apply to certain pediatric groups.

Recent Clinical Evidence

Lipifen: Recent Clinical Evidence


Evidence for Use in Primary and Secondary Cardiovascular Prevention

The research structure available for Lipifen (Atorvastatin) is based on large-scale clinical investigations. For secondary prevention, which focuses on people who have already experienced a heart attack or similar event, the evidence was gathered from major Randomized Controlled Trials (RCTs). These studies compared the treatment against less intensive approaches and were designed to track long-term health outcomes, specifically looking at the rates of subsequent serious Major Cardiovascular Events (MACE). These events included non-fatal heart attacks, strokes, and the need for heart-related procedures. Research consistently described patterns related to measured shifts in LDL-C ("bad" cholesterol) and reported differences in the occurrence rates of these major events in the observed populations.

For primary prevention, which applies to individuals with high-risk factors but no prior history of heart disease, large Placebo-Controlled RCTs were conducted. These studies were structured to compare outcomes in people taking Lipifen versus people taking an inactive pill (placebo). Research examined and monitored the first occurrence of MACE, such as a heart attack or stroke, over follow-up periods that often lasted several years. The findings describe patterns where treated groups exhibited measurements of lowered LDL-C alongside a difference in the observed event rates compared to the placebo groups. This evidence contributes to understanding the long-term patterns for high-risk individuals.


Evidence for Lipid Management and Dyslipidemia

The foundation for using Lipifen to manage conditions like Dyslipidemia and Hypercholesterolemia (high cholesterol) rests on numerous dose-ranging studies and short-term comparative clinical trials. These studies did not primarily track hard clinical events like heart attacks. Instead, they focused on biomarker shifts: measuring the treatment's impact on blood lipid levels. Specifically, research examined the magnitude of change and reduction in LDL-C, Total Cholesterol, and Triglycerides.

Findings from these trials consistently report patterns of measured changes in these lipid biomarkers over the short observation periods, which typically lasted a few months. For patients with inherited conditions like Familial Hypercholesterolemia, the research explored changes in surrogate markers of vascular health, such as carotid artery wall thickness, providing information related to the specific measurement of carotid artery wall thickness. These studies help show what has been observed so far regarding the medication's effect on measured blood fat levels.


⏳ Long-Term Studies and Durability of Follow-Up

The research on Lipifen includes observation periods that extend well beyond the initial short-term trials. The major primary and secondary prevention RCTs utilized intermediate to long-term follow-up durations, with participants often monitored for three to five years, and in some cases, for even longer extension studies. This extensive observation time was necessary to track the low-frequency Major Cardiovascular Events and to provide context for the durability of the reported changes in clinical patterns.

Key Studies & References

  1. Atorvastatin Information (HMG-CoA Reductase Inhibitor Classification)
  2. Treatment Guidelines: High Blood Cholesterol (General Statin Use)
  3. Atorvastatin Drug Information Overview (Lipid-Modifying Agent)

Frequently Asked Questions (FAQ)

Common questions about Lipifen (FAQ)

Q: What is the difference between Lipifen and generic fenofibrate?

A: Lipifen, which contains the active ingredient Atorvastatin, belongs to the statin class of medicines. Statins work primarily by blocking the enzyme responsible for cholesterol production in the liver.

Fenofibrate, in contrast, belongs to a different drug class called fibrates, which have a primary function of reducing high triglyceride levels and may also raise HDL cholesterol. These represent two distinct, officially described mechanisms for managing blood lipids.


Q: Why do some people take Lipifen for high triglycerides instead of high cholesterol?

A: Although Lipifen is widely known for lowering 'bad cholesterol' (LDL-C), official product information states that it is also indicated for the reduction of elevated triglycerides in adult patients.

This means that Lipifen may be part of the treatment plan for patients diagnosed specifically with hypertriglyceridemia and other mixed lipid disorders.


Q: Is Lipifen generally suitable for older adults?

A: Official guidelines note that individuals aged 65 years or older are a recognized risk factor for certain serious muscle effects, such as myopathy.

Regulatory documents describe that dosage selection for older populations often considers these potential risk factors, and close monitoring may be applied due to potential changes in how the body handles the drug.


Q: Why do doctors recommend continuing diet and exercise while taking Lipifen?

A: According to the official product label, Lipifen is intended to be used as an adjunct to a comprehensive lipid-lowering diet. The term 'adjunct' signifies that the medication supports the non-drug measures, rather than replacing them.

Regular exercise is often a recommended measure to help manage cholesterol levels as part of a total heart-healthy program.


Q: Does Lipifen cause dark urine or muscle tenderness for most people?

A: Muscle pain, tenderness, or weakness are potential side effects. Official safety guidelines suggest contacting a healthcare provider for such symptoms, as they can be signs of a serious, though rare, condition called rhabdomyolysis.

Dark-colored urine is also a symptom associated with this rare condition.


Q: Are there any specific foods or supplements that interact with Lipifen?

A: Regulatory documents state that consumption of large quantities of Grapefruit Juice (defined as more than 1.2 liters daily) is officially not recommended, as it can increase the drug's plasma concentration.

Excessive alcohol consumption is also associated with an increased regulatory risk of hepatic side effects.


Q: Is it necessary to take Lipifen at the same exact time every day?

A: Lipifen tablets are taken once daily. While the medication can be taken at any time of day, official patient information states that taking the medication around the same time every day may help maintain consistent and stable drug levels in the bloodstream.


Q: Is there a link between Lipifen and low levels of 'good cholesterol' (HDL)?

A: Official product information documents indicate that Lipifen is associated with a beneficial effect on lipids beyond LDL-C reduction.

The medication is documented to increase the amount of HDL cholesterol ('good cholesterol') in the blood.


Q: What does 'adjunctive therapy to diet' mean for Lipifen users?

A: The term means the medication is intended to be used in addition to and supportive of a cholesterol-lowering diet.

It is not intended to be a replacement for the recommended lifestyle modifications required for effective lipid management.


Q: Can Lipifen affect how my body absorbs other medications?

A: Official information regarding interactions notes that the effectiveness of Atorvastatin can be reduced by certain co-administered drugs like the antibiotic Rifampin.

This specific interaction requires simultaneous administration of the drugs to prevent a documented reduction in Atorvastatin's plasma levels.


Q: Does Lipifen have limitations of use related to coronary heart disease?

A: Regulatory documents include Limitations of Use stating that the full benefit of Atorvastatin on major cardiovascular events has not been determined in clinical studies for all officially indicated dyslipidemias.

This means that evidence for cardiovascular benefit is not established across every single patient group that uses the drug.


Q: Is Lipifen known to interact with other medicines used for cholesterol, like ezetimibe?

A: Yes, combining Atorvastatin with other lipid-altering agents is noted in official documents to carry a regulatory risk.

Using Lipifen with certain fibrates (like Gemfibrozil) or ezetimibe is described in regulatory documents as carrying a risk of muscle-related adverse effects (such as myopathy or rhabdomyolysis).


Q: Does Lipifen interact with common over-the-counter pain relievers?

A: Official drug labels list specific interactions with various prescription drugs and strong inhibitors of the CYP3A4 enzyme (a pathway that processes the drug).

While common over-the-counter (OTC) pain relievers are generally not listed as a contraindication, healthcare providers may review all co-administered medications and supplements, given the potential for interaction.


Q: What is Lipifen indicated for besides primary hypercholesterolemia?

A: Official indications include the prevention of cardiovascular disease (such as heart attack and stroke) in adults with multiple risk factors.

It is also indicated for the treatment of various specific lipid conditions, including mixed dyslipidemia, hypertriglyceridemia, and Homozygous Familial Hypercholesterolemia (HoFH).


Q: Can Lipifen change the way blood thinner medications work?

A: Regulatory documents note a specific interaction with the blood thinner Warfarin.

The combination may necessitate careful monitoring of coagulation tests (such as Prothrombin Time/INR), as this combination can affect blood clotting.


Q: What is the risk of developing a rash while taking Lipifen?

A: Rash is listed as a potential adverse reaction in regulatory patient information, with frequency sometimes classified as common.

If a rash is observed, particularly if it is accompanied by serious symptoms like swelling or difficulty breathing, official safety guidelines suggest seeking immediate medical attention.


Q: Can Lipifen be used by people who also have Type 2 diabetes?

A: Yes, Lipifen is officially indicated to help reduce the risk of major cardiovascular events in adult patients who have Type 2 diabetes along with multiple risk factors.

It is worth noting that the official label also mentions that statins may cause an increase in blood sugar levels.


Q: How often do the side effects of Lipifen typically go away after stopping the medication?

A: Official safety information reports that serious symptoms, such as certain muscle issues or cognitive changes that occurred while taking a statin, have been observed to be reversible upon discontinuing the medication.

However, a specific time frame for resolution is not universally provided in the regulatory text.


Q: Can people with high triglyceride levels but normal cholesterol use Lipifen?

A: Yes, Lipifen is officially indicated for adult patients with elevated triglycerides who have been diagnosed with isolated hypertriglyceridemia.

In this population, the medication is prescribed to reduce triglycerides and increase HDL cholesterol.

How should Lipifen be stored and disposed of?

How to Store and Dispose of Lipifen?

To ensure proper stability, store Lipifen capsules at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Brief temperature excursions are allowed between 15 C and 30 C (59 F and 86 F). Always keep the medication in its original container with the bottle tightly closed.

Child Safety

All medicines, including Lipifen, must be stored out of the reach of children.

Disposal

When disposing of unused or expired Lipifen, patients should follow any specific instructions provided on the prescription drug labeling. If no special instructions are given, utilize a community drug take-back program. If a take-back program is not available, mix the capsules with an undesirable substance (such as dirt or cat litter) to make them less appealing, place the mixture in a sealed bag or container, and dispose of it in the household trash. Do not flush this medication down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipifen found in:

A-Z Index: